225 related articles for article (PubMed ID: 23527823)
1. Inhaled dry powder apomorphine (VR040) for 'off ' periods in Parkinson's disease: an in-clinic double-blind dose ranging study.
Grosset KA; Malek N; Morgan F; Grosset DG
Acta Neurol Scand; 2013 Sep; 128(3):166-71. PubMed ID: 23527823
[TBL] [Abstract][Full Text] [Related]
2. Inhaled apomorphine in patients with 'on-off' fluctuations: a randomized, double-blind, placebo-controlled, clinic and home based, parallel-group study.
Grosset KA; Malek N; Morgan F; Grosset DG
J Parkinsons Dis; 2013; 3(1):31-7. PubMed ID: 23938309
[TBL] [Abstract][Full Text] [Related]
3. Phase IIa randomized double-blind, placebo-controlled study of inhaled apomorphine as acute challenge for rescuing 'off' periods in patients with established Parkinson's disease.
Grosset KA; Malek N; Morgan F; Grosset DG
Eur J Neurol; 2013 Nov; 20(11):1445-50. PubMed ID: 23350812
[TBL] [Abstract][Full Text] [Related]
4. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Chen JJ; Obering C
Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
[TBL] [Abstract][Full Text] [Related]
5. A Randomized Controlled Trial of Subcutaneous Apomorphine for Parkinson Disease: A Repeat Dose and Pharmacokinetic Study.
Nomoto M; Kubo S; Nagai M; Yamada T; Tamaoka A; Tsuboi Y; Hattori N;
Clin Neuropharmacol; 2015; 38(6):241-7. PubMed ID: 26536022
[TBL] [Abstract][Full Text] [Related]
6. Orodispersible sublingual piribedil to abort OFF episodes: a single dose placebo-controlled, randomized, double-blind, cross-over study.
Rascol O; Azulay JP; Blin O; Bonnet AM; Brefel-Courbon C; Césaro P; Damier P; Debilly B; Durif F; Galitzky M; Grouin JM; Pennaforte S; Villafane G; Yaici S; Agid Y
Mov Disord; 2010 Feb; 25(3):368-76. PubMed ID: 20063435
[TBL] [Abstract][Full Text] [Related]
7. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial.
Katzenschlager R; Poewe W; Rascol O; Trenkwalder C; Deuschl G; Chaudhuri KR; Henriksen T; van Laar T; Spivey K; Vel S; Staines H; Lees A
Lancet Neurol; 2018 Sep; 17(9):749-759. PubMed ID: 30055903
[TBL] [Abstract][Full Text] [Related]
8. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease.
Pfeiffer RF; Gutmann L; Hull KL; Bottini PB; Sherry JH;
Parkinsonism Relat Disord; 2007 Mar; 13(2):93-100. PubMed ID: 17055329
[TBL] [Abstract][Full Text] [Related]
9. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
Olanow CW; Factor SA; Espay AJ; Hauser RA; Shill HA; Isaacson S; Pahwa R; Leinonen M; Bhargava P; Sciarappa K; Navia B; Blum D;
Lancet Neurol; 2020 Feb; 19(2):135-144. PubMed ID: 31818699
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
Deleu D; Hanssens Y; Northway MG
Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose.
Pahwa R; Koller WC; Trosch RM; Sherry JH;
J Neurol Sci; 2007 Jul; 258(1-2):137-43. PubMed ID: 17466338
[TBL] [Abstract][Full Text] [Related]
12. Bilateral stimulation of the subthalamic nucleus in Parkinson's disease: surgical efficacy and prediction of outcome.
Jaggi JL; Umemura A; Hurtig HI; Siderowf AD; Colcher A; Stern MB; Baltuch GH
Stereotact Funct Neurosurg; 2004; 82(2-3):104-14. PubMed ID: 15305083
[TBL] [Abstract][Full Text] [Related]
13. [Continuous subcutaneous infusion of apomorphine in Parkinson's disease: retrospective analysis of a series of 81 patients].
Rambour M; Moreau C; Salleron J; Devos D; Kreisler A; Mutez E; Simonin C; Annic A; Dujardin K; Destée A; Defebvre L
Rev Neurol (Paris); 2014 Mar; 170(3):205-15. PubMed ID: 24594365
[TBL] [Abstract][Full Text] [Related]
14. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
15. Open-label titration of apomorphine sublingual film in patients with Parkinson's disease and "OFF" episodes.
Hui JS; Fox SH; Neeson W; Bhargava P; Pappert E; Blum D; Navia B;
Parkinsonism Relat Disord; 2020 Oct; 79():110-116. PubMed ID: 32927285
[TBL] [Abstract][Full Text] [Related]
16. The duration of the motor response to apomorphine boluses is conditioned by the length of a prior infusion in Parkinson's disease.
Vaamonde J; Flores JM; Weisser R; Ibañez R; Obeso JA
Mov Disord; 2009 Apr; 24(5):762-5. PubMed ID: 19224589
[TBL] [Abstract][Full Text] [Related]
17. Controlled-release transdermal apomorphine treatment for motor fluctuations in Parkinson's disease.
Priano L; Albani G; Calderoni S; Baudo S; Lopiano L; Rizzone M; Astolfi V; Cavalli R; Gasco MR; Fraschini F; Bergamasco B; Mauro A
Neurol Sci; 2002 Sep; 23 Suppl 2():S99-100. PubMed ID: 12548362
[TBL] [Abstract][Full Text] [Related]
18. Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection.
Hauser RA; Isaacson S; Clinch T;
Parkinsonism Relat Disord; 2014 Nov; 20(11):1171-6. PubMed ID: 25239603
[TBL] [Abstract][Full Text] [Related]
19. A double-blind study of the efficacy of apomorphine and its assessment in 'off'-periods in Parkinson's disease.
van Laar T; Jansen EN; Essink AW; Neef C; Oosterloo S; Roos RA
Clin Neurol Neurosurg; 1993 Sep; 95(3):231-5. PubMed ID: 8242966
[TBL] [Abstract][Full Text] [Related]
20. Dose response and concentration response relationship of apomorphine in patients with Parkinson's disease and end-of-dose akinesia.
Harder S; Baas H; Demisch L; Simon E
Int J Clin Pharmacol Ther; 1998 Jul; 36(7):355-62. PubMed ID: 9707348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
